Z-DEVD-FMK

Research use only, not for human use.

Z-DEVD-FMK is a specific caspase-3 inhibitor with IC50 of 18 uM; affects the survival and function of platelets in platelet concentrate during storage.

Z-DEVD-FMK is a specific caspase-3 inhibitor with IC50 of 18 uM; affects the survival and function of platelets in platelet concentrate during storage, blocks the geranylgeraniol-induced DNA fragmentation in human leukemia cells; abolishes the apoptosis, CPP32/Mch3alpha processing and the increase in CPP32-like protease activity induced by TGF-beta1 in rat hepatocytes.(In Vitro):N27 cells are exposed to MPP+ in the absence or presence of 50 μM Z-DIPD-FMK or 100 μM Z-DEVD-FMK or 50 μM Z-LEHD-FMK and then caspase-9 and caspase-3 enzymatic activities are determined by enzymatic assay at 12 and 24 h following exposure, respectively. Exposure to 300 μM MPP+ for 24 h in N27 cells results in an approximately 2.5-fold increase in caspase-3 enzyme activity. MPP+-induced increases in caspase-3 enzyme activity are significantly blocked by 50 μM Z-DIPD-FMK, 100 μM Z-DEVD-FMK, and 50 μM Z-LEHD-FMK.(In Vivo):Early Z-DEVD-FMK (160 ng) treatment improves motor and cognitive function after traumatic CNS injury induced by severe controlled cortical impact (CCI) in the mouse. Treatment with Z-DEVD-FMK (160 ng) significantly improves neurological outcome when compared with traumatized animals treated with DMSO vehicle (p<0.01).

N27 cells are exposed to MPP+ in the absence or presence of 50 μM Z-DIPD-FMK or 100 μM Z-DEVD-FMK or 50 μM Z-LEHD-FMK and then caspase-9 and caspase-3 enzymatic activities are determined by enzymatic assay at 12 and 24 h following exposure, respectively. Exposure to 300 μM MPP+ for 24 h in N27 cells results in an approximately 2.5-fold increase in caspase-3 enzyme activity. MPP+-induced increases in caspase-3 enzyme activity are significantly blocked by 50 μM Z-DIPD-FMK, 100 μM Z-DEVD-FMK, and 50 μM Z-LEHD-FMK.

Early Z-DEVD-FMK (160 ng) treatment improves motor and cognitive function after traumatic CNS injury induced by severe controlled cortical impact (CCI) in the mouse. Treatment with Z-DEVD-FMK (160 ng) significantly improves neurological outcome when compared with traumatized animals treated with DMSO vehicle (p<0.01).

Z-DEVD-fmk | Z DEVD fmk | ZDEVDfmk

Apoptosis

Caspase

Caspase-3

Cancer

——

210344-95-9

668.6646

C30H41FN4O12

>98% (HPLC)

DMSO: ≥ 33.33 mg/mL

O=C(OC)CC[C@H](NC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(OC)=O)=O)C(N[C@@H](C(C)C)C(N[C@H](C(CF)=O)CC(OC)=O)=O)=O

L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-α-aspartyl-L-α-glutamyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, 1,2-dimethyl ester

(-20℃)

With Ice Pack

≥ 2 years